HEADER VIRAL PROTEIN 20-DEC-06 2OC7 TITLE STRUCTURE OF HEPATITIS C VIRAL NS3 PROTEASE DOMAIN COMPLEXED WITH NS4A TITLE 2 PEPTIDE AND KETOAMIDE SCH571696 COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEPATITIS C VIRUS; COMPND 3 CHAIN: A, C; COMPND 4 ENGINEERED: YES; COMPND 5 MOL_ID: 2; COMPND 6 MOLECULE: HEPATITIS C VIRUS; COMPND 7 CHAIN: B, D; COMPND 8 ENGINEERED: YES; COMPND 9 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HEPATITIS C VIRUS; SOURCE 3 ORGANISM_TAXID: 11103; SOURCE 4 GENE: NS3; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: BLR(DE3); SOURCE 8 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 9 EXPRESSION_SYSTEM_VECTOR: PET-3A; SOURCE 10 MOL_ID: 2; SOURCE 11 SYNTHETIC: YES KEYWDS HEPATITIS C VIRUS, HCV, NS3 PROTEASE DOMAIN, KETOAMIDE INHIBITOR, KEYWDS 2 VIRAL PROTEIN EXPDTA X-RAY DIFFRACTION AUTHOR A.J.PRONGAY,Z.GUO,N.YAO,T.FISCHMANN,C.STRICKLAND,J.MYERS JR., AUTHOR 2 P.C.WEBER,B.MALCOLM,B.M.BEYER,R.INGRAM,J.PICHARDO,Z.HONG, AUTHOR 3 W.W.PROSISE,L.RAMANATHAN,S.S.TAREMI,T.YAROSH-TOMAINE,R.ZHANG, AUTHOR 4 M.SENIOR,R.YANG,A.ARASAPPAN,F.BENNETT,S.F.BOGEN,K.CHEN,E.JAO,Y.LIU, AUTHOR 5 R.G.LOVE,A.K.SAKSENA,S.VENKATRAMAN,V.GIRIJAVALLABHAN,F.G.NJOROGE, AUTHOR 6 V.MADISON REVDAT 5 30-AUG-23 2OC7 1 REMARK SEQADV LINK REVDAT 4 22-FEB-12 2OC7 1 AUTHOR REMARK REVDAT 3 13-JUL-11 2OC7 1 VERSN REVDAT 2 24-FEB-09 2OC7 1 VERSN REVDAT 1 31-JUL-07 2OC7 0 JRNL AUTH A.J.PRONGAY,Z.GUO,N.YAO,J.PICHARDO,T.FISCHMANN,C.STRICKLAND, JRNL AUTH 2 J.MYERS JR.,P.C.WEBER,B.M.BEYER,R.INGRAM,Z.HONG,W.W.PROSISE, JRNL AUTH 3 L.RAMANATHAN,S.S.TAREMI,T.YAROSH-TOMAINE,R.ZHANG,M.SENIOR, JRNL AUTH 4 R.S.YANG,B.MALCOLM,A.ARASAPPAN,F.BENNETT,S.L.BOGEN,K.CHEN, JRNL AUTH 5 E.JAO,Y.T.LIU,R.G.LOVEY,A.K.SAKSENA,S.VENKATRAMAN, JRNL AUTH 6 V.GIRIJAVALLABHAN,F.G.NJOROGE,V.MADISON JRNL TITL DISCOVERY OF THE HCV NS3/4A PROTEASE INHIBITOR JRNL TITL 2 (1R,5S)-N-[3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]-3- JRNL TITL 3 [2(S)-[[[(1,1-DIMETHYLETHYL)AMINO]CARBONYL]AMINO]-3, JRNL TITL 4 3-DIMETHYL-1-OXOBUTYL]- JRNL TITL 5 6,6-DIMETHYL-3-AZABICYCLO[3.1.0]HEXAN-2(S)-CARBOXAMIDE (SCH JRNL TITL 6 503034) II. KEY STEPS IN STRUCTURE-BASED OPTIMIZATION. JRNL REF J.MED.CHEM. V. 50 2310 2007 JRNL REFN ISSN 0022-2623 JRNL PMID 17444623 JRNL DOI 10.1021/JM060173K REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH J.L.KIM,K.A.MORGENSTERN,C.LIN,T.FOX,M.D.DWYER,J.A.LANDRO, REMARK 1 AUTH 2 S.P.CHAMBERS,W.MARKLAND,C.A.LEPRE,E.T.O'MALLEY,S.L.HARBESON, REMARK 1 AUTH 3 C.M.RICE,M.A.MURCKO,P.R.CARON,J.A.THOMSON REMARK 1 TITL CRYSTAL STRUCTURE OF THE HEPATITIS C VIRUS NS3 PROTEASE REMARK 1 TITL 2 DOMAIN COMPLEXED WITH A SYNTHETIC NS4A COFACTOR PEPTIDE. REMARK 1 REF CELL(CAMBRIDGE,MASS.) V. 87 343 1996 REMARK 1 REFN ISSN 0092-8674 REMARK 1 PMID 8861917 REMARK 1 DOI 10.1016/S0092-8674(00)81351-3 REMARK 1 REFERENCE 2 REMARK 1 AUTH A.ARASAPPAN,F.G.NJOROGE,T.Y.CHAN,F.BENNETT,S.L.BOGEN,K.CHEN, REMARK 1 AUTH 2 H.GU,L.HONG,E.JAO,Y.T.LIU,R.G.LOVEY,T.PAREKH,R.E.PIKE, REMARK 1 AUTH 3 P.PINTO,B.SANTHANAM,S.VENKATRAMAN,H.VACCARO,H.WANG,X.YANG, REMARK 1 AUTH 4 Z.ZHU,B.MCKITTRICK,A.K.SAKSENA,V.GIRIJAVALLABHAN,J.PICHARDO, REMARK 1 AUTH 5 N.BUTKIEWICZ,R.INGRAM,B.MALCOLM,A.PRONGAY,N.YAO,B.MARTEN, REMARK 1 AUTH 6 V.MADISON,S.KEMP,O.LEVY,M.LIM-WILBY,S.TAMURA,A.K.GANGULY REMARK 1 TITL HEPATITIS C VIRUS NS3-4A SERINE PROTEASE INHIBITORS: SAR OF REMARK 1 TITL 2 P'2 MOIETY WITH IMPROVED POTENCY. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 15 4180 2005 REMARK 1 REFN ISSN 0960-894X REMARK 1 PMID 16087332 REMARK 1 DOI 10.1016/J.BMCL.2005.06.091 REMARK 1 REFERENCE 3 REMARK 1 AUTH K.X.CHEN,F.G.NJOROGE,A.PRONGAY,J.PICHARDO,V.MADISON, REMARK 1 AUTH 2 V.GIRIJAVALLABHAN REMARK 1 TITL SYNTHESIS AND BIOLOGICAL ACTIVITY OF MACROCYCLIC INHIBITORS REMARK 1 TITL 2 OF HEPATITIS C VIRUS (HCV) NS3 PROTEASE. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 15 4475 2005 REMARK 1 REFN ISSN 0960-894X REMARK 1 PMID 16112859 REMARK 1 DOI 10.1016/J.BMCL.2005.07.033 REMARK 1 REFERENCE 4 REMARK 1 AUTH S.BOGEN,A.K.SAKSENA,A.ARASAPPAN,H.GU,F.G.NJOROGE, REMARK 1 AUTH 2 V.GIRIJAVALLABHAN,J.PICHARDO,N.BUTKIEWICZ,A.PRONGAY, REMARK 1 AUTH 3 V.MADISON REMARK 1 TITL HEPATITIS C VIRUS NS3-4A SERINE PROTEASE INHIBITORS: USE OF REMARK 1 TITL 2 A P2-P1 CYCLOPROPYL ALANINE COMBINATION FOR IMPROVED REMARK 1 TITL 3 POTENCY. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 15 4515 2005 REMARK 1 REFN ISSN 0960-894X REMARK 1 PMID 16112862 REMARK 1 DOI 10.1016/J.BMCL.2005.07.009 REMARK 1 REFERENCE 5 REMARK 1 AUTH S.L.BOGEN,S.RUAN,R.LIU,S.AGRAWAL,J.PICHARDO,A.PRONGAY, REMARK 1 AUTH 2 B.BAROUDY,A.K.SAKSENA,V.GIRIJAVALLABHAN,F.G.NJOROGE REMARK 1 TITL DEPEPTIDIZATION EFFORTS ON P3-P2' ALPHA-KETOAMIDE INHIBITORS REMARK 1 TITL 2 OF HCV NS3-4A SERINE PROTEASE: EFFECT ON HCV REPLICON REMARK 1 TITL 3 ACTIVITY. REMARK 1 REF BIOORG.MED.CHEM.LETT. V. 16 1621 2006 REMARK 1 REFN ISSN 0960-894X REMARK 1 PMID 16387495 REMARK 1 DOI 10.1016/J.BMCL.2005.12.013 REMARK 2 REMARK 2 RESOLUTION. 2.70 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR 98.1 REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.70 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 8.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 1.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 79.3 REMARK 3 NUMBER OF REFLECTIONS : 15905 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.193 REMARK 3 FREE R VALUE : 0.293 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 1573 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.70 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.82 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 37.40 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : 0.3092 REMARK 3 BIN FREE R VALUE : 0.4824 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : 76 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2724 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 46 REMARK 3 SOLVENT ATOMS : 135 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 35.20 REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 BOND ANGLES (DEGREES) : 1.855 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : 1.467 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : ISOTROPIC REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NULL REMARK 4 REMARK 4 2OC7 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 09-MAR-07. REMARK 100 THE DEPOSITION ID IS D_1000040952. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 95 REMARK 200 PH : 5.6 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : APS REMARK 200 BEAMLINE : 17-ID REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.00 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC QUANTUM 210 REMARK 200 INTENSITY-INTEGRATION SOFTWARE : HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 18800 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.700 REMARK 200 RESOLUTION RANGE LOW (A) : 50.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 93.8 REMARK 200 DATA REDUNDANCY : 3.600 REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : 0.04300 REMARK 200 FOR THE DATA SET : 23.8000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.70 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : NULL REMARK 200 COMPLETENESS FOR SHELL (%) : 56.4 REMARK 200 DATA REDUNDANCY IN SHELL : 3.60 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.26700 REMARK 200 FOR SHELL : 2.200 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MIR REMARK 200 SOFTWARE USED: X-PLOR REMARK 200 STARTING MODEL: 2O8M REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 68.33 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.88 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: THE PROTEIN (NS3 COMPLEXED WITH KK REMARK 280 -NS4A(21-39)-KK PEPTIDE) WAS AT 12-15 MG/ML IN 15 MM MES, PH 6.5, REMARK 280 1 M NACL, 20 MM B-MERCAPTOETHANOL. HANGING DROPS WERE FORMED BY REMARK 280 MIXING 4:L PROTEIN SOLUTION WITH 4:L {0.75-1.0 M NACL, 0.1M NA/K REMARK 280 PHOSPHATE, 0.1 M MES, PH 5.8-6.1, 20 MM 2-MERCAPTOETHANOL} THE REMARK 280 DROP WAS EQUILIBRATED THE DROPS OVER 1 ML {(1.25-1.50 M) NACL - REMARK 280 0.1M NA/K PHOSPHATE 0.1 M MES, PH 5.6-5.8, 20 MM 2- REMARK 280 MERCAPTOETHANOL} , VAPOR DIFFUSION, HANGING DROP, TEMPERATURE REMARK 280 277K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: H 3 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z REMARK 290 3555 -X+Y,-X,Z REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z REMARK 290 6555 -X,-X+Y,-Z REMARK 290 7555 X+2/3,Y+1/3,Z+1/3 REMARK 290 8555 -Y+2/3,X-Y+1/3,Z+1/3 REMARK 290 9555 -X+Y+2/3,-X+1/3,Z+1/3 REMARK 290 10555 Y+2/3,X+1/3,-Z+1/3 REMARK 290 11555 X-Y+2/3,-Y+1/3,-Z+1/3 REMARK 290 12555 -X+2/3,-X+Y+1/3,-Z+1/3 REMARK 290 13555 X+1/3,Y+2/3,Z+2/3 REMARK 290 14555 -Y+1/3,X-Y+2/3,Z+2/3 REMARK 290 15555 -X+Y+1/3,-X+2/3,Z+2/3 REMARK 290 16555 Y+1/3,X+2/3,-Z+2/3 REMARK 290 17555 X-Y+1/3,-Y+2/3,-Z+2/3 REMARK 290 18555 -X+1/3,-X+Y+2/3,-Z+2/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 7 1.000000 0.000000 0.000000 112.33800 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 64.85837 REMARK 290 SMTRY3 7 0.000000 0.000000 1.000000 25.20133 REMARK 290 SMTRY1 8 -0.500000 -0.866025 0.000000 112.33800 REMARK 290 SMTRY2 8 0.866025 -0.500000 0.000000 64.85837 REMARK 290 SMTRY3 8 0.000000 0.000000 1.000000 25.20133 REMARK 290 SMTRY1 9 -0.500000 0.866025 0.000000 112.33800 REMARK 290 SMTRY2 9 -0.866025 -0.500000 0.000000 64.85837 REMARK 290 SMTRY3 9 0.000000 0.000000 1.000000 25.20133 REMARK 290 SMTRY1 10 -0.500000 0.866025 0.000000 112.33800 REMARK 290 SMTRY2 10 0.866025 0.500000 0.000000 64.85837 REMARK 290 SMTRY3 10 0.000000 0.000000 -1.000000 25.20133 REMARK 290 SMTRY1 11 1.000000 0.000000 0.000000 112.33800 REMARK 290 SMTRY2 11 0.000000 -1.000000 0.000000 64.85837 REMARK 290 SMTRY3 11 0.000000 0.000000 -1.000000 25.20133 REMARK 290 SMTRY1 12 -0.500000 -0.866025 0.000000 112.33800 REMARK 290 SMTRY2 12 -0.866025 0.500000 0.000000 64.85837 REMARK 290 SMTRY3 12 0.000000 0.000000 -1.000000 25.20133 REMARK 290 SMTRY1 13 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 13 0.000000 1.000000 0.000000 129.71675 REMARK 290 SMTRY3 13 0.000000 0.000000 1.000000 50.40267 REMARK 290 SMTRY1 14 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 14 0.866025 -0.500000 0.000000 129.71675 REMARK 290 SMTRY3 14 0.000000 0.000000 1.000000 50.40267 REMARK 290 SMTRY1 15 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 15 -0.866025 -0.500000 0.000000 129.71675 REMARK 290 SMTRY3 15 0.000000 0.000000 1.000000 50.40267 REMARK 290 SMTRY1 16 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 16 0.866025 0.500000 0.000000 129.71675 REMARK 290 SMTRY3 16 0.000000 0.000000 -1.000000 50.40267 REMARK 290 SMTRY1 17 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 17 0.000000 -1.000000 0.000000 129.71675 REMARK 290 SMTRY3 17 0.000000 0.000000 -1.000000 50.40267 REMARK 290 SMTRY1 18 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 18 -0.866025 0.500000 0.000000 129.71675 REMARK 290 SMTRY3 18 0.000000 0.000000 -1.000000 50.40267 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TETRAMERIC REMARK 350 SOFTWARE USED: PISA,PQS REMARK 350 TOTAL BURIED SURFACE AREA: 7740 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 15180 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -127.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C, D REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A -10 REMARK 465 ALA A -9 REMARK 465 SER A -8 REMARK 465 MET A -7 REMARK 465 THR A -6 REMARK 465 GLY A -5 REMARK 465 GLY A -4 REMARK 465 GLN A -3 REMARK 465 GLN A -2 REMARK 465 MET A -1 REMARK 465 GLY A 0 REMARK 465 GLY A 182 REMARK 465 SER A 183 REMARK 465 HIS A 184 REMARK 465 HIS A 185 REMARK 465 HIS A 186 REMARK 465 HIS A 187 REMARK 465 HIS A 188 REMARK 465 HIS A 189 REMARK 465 LYS B 19 REMARK 465 MET C -10 REMARK 465 ALA C -9 REMARK 465 SER C -8 REMARK 465 MET C -7 REMARK 465 THR C -6 REMARK 465 GLY C -5 REMARK 465 GLY C -4 REMARK 465 GLN C -3 REMARK 465 GLN C -2 REMARK 465 MET C -1 REMARK 465 GLY C 0 REMARK 465 ALA C 1 REMARK 465 PRO C 2 REMARK 465 ILE C 3 REMARK 465 THR C 4 REMARK 465 ALA C 5 REMARK 465 TYR C 6 REMARK 465 ALA C 7 REMARK 465 GLN C 8 REMARK 465 GLN C 9 REMARK 465 THR C 10 REMARK 465 ARG C 11 REMARK 465 GLY C 12 REMARK 465 LEU C 13 REMARK 465 LEU C 14 REMARK 465 GLY C 15 REMARK 465 CYS C 16 REMARK 465 ILE C 17 REMARK 465 ILE C 18 REMARK 465 THR C 19 REMARK 465 SER C 20 REMARK 465 LEU C 21 REMARK 465 THR C 22 REMARK 465 GLY C 23 REMARK 465 ARG C 24 REMARK 465 ASP C 25 REMARK 465 LYS C 26 REMARK 465 ASN C 27 REMARK 465 GLN C 28 REMARK 465 ARG C 180 REMARK 465 SER C 181 REMARK 465 GLY C 182 REMARK 465 SER C 183 REMARK 465 HIS C 184 REMARK 465 HIS C 185 REMARK 465 HIS C 186 REMARK 465 HIS C 187 REMARK 465 HIS C 188 REMARK 465 HIS C 189 REMARK 465 LYS D 19 REMARK 465 LYS D 20 REMARK 465 ILE D 37 REMARK 465 ILE D 38 REMARK 465 PRO D 39 REMARK 465 LYS D 40 REMARK 465 LYS D 41 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 ZN ZN A 901 O HOH A 1000 1.52 REMARK 500 SG CYS A 16 S2 BME A 801 2.03 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 THR A 38 -167.24 -109.60 REMARK 500 HIS A 57 7.46 -65.06 REMARK 500 GLN A 89 109.17 -56.38 REMARK 500 SER A 101 136.78 84.95 REMARK 500 PRO B 35 137.63 -39.57 REMARK 500 ASN C 77 84.69 -163.08 REMARK 500 PRO C 88 -176.92 -65.38 REMARK 500 ALA C 111 31.96 71.93 REMARK 500 PHE C 154 109.25 -53.62 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ZN A 901 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE ZN C 901 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE BME A 801 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE HU4 A 999 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2OBO RELATED DB: PDB REMARK 900 STRUCTURE OF HCV NS3-NS4A COMPLEXED WITH KETOAMIDE SCH476776 REMARK 900 RELATED ID: 2OC1 RELATED DB: PDB REMARK 900 STRUCTURE OF HCV NS3-NS4A COMPLEXED WITH KETOAMIDE CVS4819 REMARK 900 RELATED ID: 2OC0 RELATED DB: PDB REMARK 900 STRUCTURE OF HCV NS3-NS4A COMPLEXED WITH KETOAMIDE SCH491762 DBREF 2OC7 A 1 181 UNP Q9ELS8 Q9ELS8_9HEPC 1027 1207 DBREF 2OC7 C 1 181 UNP Q9ELS8 Q9ELS8_9HEPC 1027 1207 DBREF 2OC7 B 21 39 UNP Q9QP06 Q9QP06_9HEPC 1678 1696 DBREF 2OC7 D 21 39 UNP Q9QP06 Q9QP06_9HEPC 1678 1696 SEQADV 2OC7 MET A -10 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 ALA A -9 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 SER A -8 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 MET A -7 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 THR A -6 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLY A -5 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLY A -4 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLN A -3 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLN A -2 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 MET A -1 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLY A 0 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 ARG A 119 UNP Q9ELS8 GLN 1145 CONFLICT SEQADV 2OC7 GLY A 182 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 SER A 183 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 HIS A 184 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS A 185 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS A 186 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS A 187 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS A 188 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS A 189 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 MET C -10 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 ALA C -9 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 SER C -8 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 MET C -7 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 THR C -6 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLY C -5 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLY C -4 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLN C -3 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLN C -2 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 MET C -1 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 GLY C 0 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 ARG C 119 UNP Q9ELS8 GLN 1145 CONFLICT SEQADV 2OC7 GLY C 182 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 SER C 183 UNP Q9ELS8 CLONING ARTIFACT SEQADV 2OC7 HIS C 184 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS C 185 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS C 186 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS C 187 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS C 188 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 HIS C 189 UNP Q9ELS8 EXPRESSION TAG SEQADV 2OC7 LYS B 19 UNP Q9QP06 CLONING ARTIFACT SEQADV 2OC7 LYS B 20 UNP Q9QP06 CLONING ARTIFACT SEQADV 2OC7 LYS B 40 UNP Q9QP06 CLONING ARTIFACT SEQADV 2OC7 LYS B 41 UNP Q9QP06 CLONING ARTIFACT SEQADV 2OC7 LYS D 19 UNP Q9QP06 CLONING ARTIFACT SEQADV 2OC7 LYS D 20 UNP Q9QP06 CLONING ARTIFACT SEQADV 2OC7 LYS D 40 UNP Q9QP06 CLONING ARTIFACT SEQADV 2OC7 LYS D 41 UNP Q9QP06 CLONING ARTIFACT SEQRES 1 A 200 MET ALA SER MET THR GLY GLY GLN GLN MET GLY ALA PRO SEQRES 2 A 200 ILE THR ALA TYR ALA GLN GLN THR ARG GLY LEU LEU GLY SEQRES 3 A 200 CYS ILE ILE THR SER LEU THR GLY ARG ASP LYS ASN GLN SEQRES 4 A 200 VAL GLU GLY GLU VAL GLN ILE VAL SER THR ALA THR GLN SEQRES 5 A 200 THR PHE LEU ALA THR CYS ILE ASN GLY VAL CYS TRP THR SEQRES 6 A 200 VAL TYR HIS GLY ALA GLY THR ARG THR ILE ALA SER PRO SEQRES 7 A 200 LYS GLY PRO VAL ILE GLN MET TYR THR ASN VAL ASP GLN SEQRES 8 A 200 ASP LEU VAL GLY TRP PRO ALA PRO GLN GLY SER ARG SER SEQRES 9 A 200 LEU THR PRO CYS THR CYS GLY SER SER ASP LEU TYR LEU SEQRES 10 A 200 VAL THR ARG HIS ALA ASP VAL ILE PRO VAL ARG ARG ARG SEQRES 11 A 200 GLY ASP SER ARG GLY SER LEU LEU SER PRO ARG PRO ILE SEQRES 12 A 200 SER TYR LEU LYS GLY SER SER GLY GLY PRO LEU LEU CYS SEQRES 13 A 200 PRO ALA GLY HIS ALA VAL GLY LEU PHE ARG ALA ALA VAL SEQRES 14 A 200 CYS THR ARG GLY VAL ALA LYS ALA VAL ASP PHE ILE PRO SEQRES 15 A 200 VAL GLU ASN LEU GLU THR THR MET ARG SER GLY SER HIS SEQRES 16 A 200 HIS HIS HIS HIS HIS SEQRES 1 B 23 LYS LYS GLY SER VAL VAL ILE VAL GLY ARG ILE VAL LEU SEQRES 2 B 23 SER GLY LYS PRO ALA ILE ILE PRO LYS LYS SEQRES 1 C 200 MET ALA SER MET THR GLY GLY GLN GLN MET GLY ALA PRO SEQRES 2 C 200 ILE THR ALA TYR ALA GLN GLN THR ARG GLY LEU LEU GLY SEQRES 3 C 200 CYS ILE ILE THR SER LEU THR GLY ARG ASP LYS ASN GLN SEQRES 4 C 200 VAL GLU GLY GLU VAL GLN ILE VAL SER THR ALA THR GLN SEQRES 5 C 200 THR PHE LEU ALA THR CYS ILE ASN GLY VAL CYS TRP THR SEQRES 6 C 200 VAL TYR HIS GLY ALA GLY THR ARG THR ILE ALA SER PRO SEQRES 7 C 200 LYS GLY PRO VAL ILE GLN MET TYR THR ASN VAL ASP GLN SEQRES 8 C 200 ASP LEU VAL GLY TRP PRO ALA PRO GLN GLY SER ARG SER SEQRES 9 C 200 LEU THR PRO CYS THR CYS GLY SER SER ASP LEU TYR LEU SEQRES 10 C 200 VAL THR ARG HIS ALA ASP VAL ILE PRO VAL ARG ARG ARG SEQRES 11 C 200 GLY ASP SER ARG GLY SER LEU LEU SER PRO ARG PRO ILE SEQRES 12 C 200 SER TYR LEU LYS GLY SER SER GLY GLY PRO LEU LEU CYS SEQRES 13 C 200 PRO ALA GLY HIS ALA VAL GLY LEU PHE ARG ALA ALA VAL SEQRES 14 C 200 CYS THR ARG GLY VAL ALA LYS ALA VAL ASP PHE ILE PRO SEQRES 15 C 200 VAL GLU ASN LEU GLU THR THR MET ARG SER GLY SER HIS SEQRES 16 C 200 HIS HIS HIS HIS HIS SEQRES 1 D 23 LYS LYS GLY SER VAL VAL ILE VAL GLY ARG ILE VAL LEU SEQRES 2 D 23 SER GLY LYS PRO ALA ILE ILE PRO LYS LYS HET ZN A 901 1 HET BME A 801 4 HET HU4 A 999 40 HET ZN C 901 1 HETNAM ZN ZINC ION HETNAM BME BETA-MERCAPTOETHANOL HETNAM HU4 TERT-BUTYL {(1S)-2-[(1R,2S,5R)-2-({[(1S)-3-AMINO-1- HETNAM 2 HU4 (CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL]AMINO}CARBONYL)-7, HETNAM 3 HU4 7-DIMETHYL-6-OXA-3-AZABICYCLO[3.2.0]HEPT-3-YL]-1- HETNAM 4 HU4 CYCLOHEXYL-2-OXOETHYL}CARBAMATE HETSYN HU4 KETOAMIDE INHIBITOR SCH571696, BOUND FORM FORMUL 5 ZN 2(ZN 2+) FORMUL 6 BME C2 H6 O S FORMUL 7 HU4 C29 H46 N4 O7 FORMUL 9 HOH *135(H2 O) HELIX 1 1 GLY A 12 GLY A 23 1 12 HELIX 2 2 TYR A 56 GLY A 60 1 5 HELIX 3 3 ILE A 132 LYS A 136 1 5 HELIX 4 4 VAL A 172 ARG A 180 1 9 HELIX 5 5 TYR C 56 GLY C 60 1 5 HELIX 6 6 SER C 133 LEU C 135 5 3 HELIX 7 7 VAL C 172 MET C 179 1 8 SHEET 1 A 4 TYR A 6 GLN A 9 0 SHEET 2 A 4 SER B 22 VAL B 30 -1 O ARG B 28 N GLN A 8 SHEET 3 A 4 THR A 63 SER A 66 1 N THR A 63 O VAL B 23 SHEET 4 A 4 GLY A 69 VAL A 71 -1 O VAL A 71 N ILE A 64 SHEET 1 B 7 TYR A 6 GLN A 9 0 SHEET 2 B 7 SER B 22 VAL B 30 -1 O ARG B 28 N GLN A 8 SHEET 3 B 7 VAL A 33 SER A 37 -1 N SER A 37 O VAL B 24 SHEET 4 B 7 THR A 42 ILE A 48 -1 O ALA A 45 N GLN A 34 SHEET 5 B 7 VAL A 51 VAL A 55 -1 O TRP A 53 N THR A 46 SHEET 6 B 7 LEU A 82 PRO A 86 -1 O TRP A 85 N CYS A 52 SHEET 7 B 7 TYR A 75 ASN A 77 -1 N ASN A 77 O LEU A 82 SHEET 1 C 7 ASP A 103 VAL A 107 0 SHEET 2 C 7 VAL A 113 ARG A 118 -1 O VAL A 116 N LEU A 104 SHEET 3 C 7 ARG A 123 PRO A 131 -1 O SER A 125 N ARG A 117 SHEET 4 C 7 VAL A 163 PRO A 171 -1 O LYS A 165 N LEU A 126 SHEET 5 C 7 ALA A 150 THR A 160 -1 N VAL A 158 O ALA A 166 SHEET 6 C 7 PRO A 142 LEU A 144 -1 N LEU A 143 O VAL A 151 SHEET 7 C 7 ASP A 103 VAL A 107 -1 N TYR A 105 O LEU A 144 SHEET 1 D 3 ALA B 36 ILE B 37 0 SHEET 2 D 3 SER D 22 VAL D 30 -1 O VAL D 30 N ALA B 36 SHEET 3 D 3 THR C 63 ILE C 64 1 N THR C 63 O VAL D 23 SHEET 1 E 7 ALA B 36 ILE B 37 0 SHEET 2 E 7 SER D 22 VAL D 30 -1 O VAL D 30 N ALA B 36 SHEET 3 E 7 VAL C 33 SER C 37 -1 N ILE C 35 O VAL D 26 SHEET 4 E 7 THR C 42 ILE C 48 -1 O ALA C 45 N GLN C 34 SHEET 5 E 7 VAL C 51 VAL C 55 -1 O TRP C 53 N THR C 46 SHEET 6 E 7 LEU C 82 PRO C 86 -1 O TRP C 85 N CYS C 52 SHEET 7 E 7 TYR C 75 ASN C 77 -1 N TYR C 75 O GLY C 84 SHEET 1 F 7 ASP C 103 VAL C 107 0 SHEET 2 F 7 VAL C 113 GLY C 120 -1 O ILE C 114 N LEU C 106 SHEET 3 F 7 ARG C 123 PRO C 131 -1 O SER C 125 N ARG C 117 SHEET 4 F 7 VAL C 163 PRO C 171 -1 O VAL C 167 N GLY C 124 SHEET 5 F 7 ALA C 150 THR C 160 -1 N ALA C 156 O ASP C 168 SHEET 6 F 7 PRO C 142 LEU C 144 -1 N LEU C 143 O VAL C 151 SHEET 7 F 7 ASP C 103 VAL C 107 -1 N TYR C 105 O LEU C 144 LINK OG SER A 139 C37 HU4 A 999 1555 1555 1.43 SITE 1 AC1 6 CYS A 97 THR A 98 CYS A 99 SER A 101 SITE 2 AC1 6 CYS A 145 HOH A1000 SITE 1 AC2 4 CYS C 97 CYS C 99 CYS C 145 HOH C 912 SITE 1 AC3 3 CYS A 16 ILE A 17 ALA A 39 SITE 1 AC4 13 GLN A 41 HIS A 57 ARG A 123 LEU A 135 SITE 2 AC4 13 GLY A 137 SER A 138 SER A 139 PHE A 154 SITE 3 AC4 13 ARG A 155 ALA A 156 ALA A 157 CYS A 159 SITE 4 AC4 13 ASP A 168 CRYST1 224.676 224.676 75.604 90.00 90.00 120.00 H 3 2 36 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.004451 0.002569 0.000000 0.00000 SCALE2 0.000000 0.005139 0.000000 0.00000 SCALE3 0.000000 0.000000 0.013227 0.00000